[Dimeric bisbenzimidazoles suppress the herpes simplex virus and human cytomegalovirus infections in cell сultures].
Regina R KlimovaE D MomotyukNatalya A DemidovaYa Yu ChernoryzhVasily KovalA A IvanovA L ZhuzeVladimir T Valuev-EllistonPublished in: Voprosy virusologii (2018)
Antiviral activity of new AТ-specific fluorescent symmetric dimeric bisbenzimidazoles of DBА(n) series was assessed in the cell models of infections caused by type 1 herpes simplex virus (HSV1) and human cytomegalovirus (CMV). In DBA(n) molecules bisbenzimidazole fragments are bound to an oligomethylene liner with varied number of methylene groups in the linker (n = 1, 3, 5, 7, 9, 11). In contrast to DB(n) dimeric bisbenzimidazoles, in DBA(n) series terminal fragments of macromolecules contain N-dimethylaminopropylcarboxamide groups instead of N-methylpiperazine groups. DBА(n) compounds better dissolve in water, pass across plasma and nuclear membrane, and stain DNA in living cells. DBA(1) and DBA(7) produced therapeutic effects in HSV1 infection; DBA(7) completely suppressed the infection. DBA(11) displayed in vitro therapeutic activity in HSV1 and CMV infections. In addition, DBA(7) and DBA(1) showed microbicidal activity. Thus, DBA(11), which is active against two viruses causing severe diseases with serious health consequences for immunodeficient individuals, should be further investigated. High antiviral activity of DBA(7) in all test models indicates that this compound is a promising active agent for innovative antiviral drugs.
Keyphrases
- herpes simplex virus
- living cells
- endothelial cells
- single cell
- healthcare
- magnetic resonance
- cell therapy
- stem cells
- epstein barr virus
- computed tomography
- climate change
- mesenchymal stem cells
- health information
- risk assessment
- induced pluripotent stem cells
- early onset
- diffuse large b cell lymphoma
- bone marrow
- circulating tumor